Please Note: This trial is no longer enrolling new participants
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
| Protocol No. | CTO-EA1181 | Scope | National |
|---|---|---|---|
| Principal Investigator | Kathy Miller | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase II |
